AEON Biopharma, Inc. (AEON)
(Real Time Quote from BATS)
$2.36 USD
+0.11 (4.89%)
Updated Jul 22, 2024 02:52 PM ET
3-Hold of 5 3
F Value C Growth B Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
AEON 2.36 +0.11(4.89%)
Will AEON be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for AEON based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for AEON
Down -64.16% in 4 Weeks, Here's Why AEON Biopharma, Inc. (AEON) Looks Ripe for a Turnaround
AEON Biopharma, Inc. (AEON) Loses -79.2% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
AEON: What are Zacks experts saying now?
Zacks Private Portfolio Services
Here's Why AEON Biopharma, Inc. (AEON) Is a Great 'Buy the Bottom' Stock Now
Other News for AEON
3 Penny Stocks to Watch Now, 7/18/24
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
AEON Biopharma Announces Strategic Reprioritization to Pursue a Biosimilar Pathway for ABP-450
Buy Rating Affirmed for AEON Biopharma: Strategic Cost-Cutting and ABP-450’s Broad Market Potential
AEON Biopharma Announces Strategic Resource Reprioritization and Cost Reduction Plan